Edwards Lifesciences vs Zoetis

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (78 vs 79)
Edwards Lifesciences logo

Edwards Lifesciences

LeaderHealthcare Tech

Enterprise

Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.

AI VisibilityBeta
Overall Score
B78
Category Rank
#41 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
74
Gemini
82

About

Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.

Full profile
Zoetis logo

Zoetis

LeaderHealthcare Tech

Animal Health

Zoetis (ZTS) reported ~$9.1B revenue in FY2024. World's largest animal health company developing medicines, vaccines, and diagnostics for companion animals and livestock. HQ: Parsippany, NJ.

AI VisibilityBeta
Overall Score
B79
Category Rank
#31 of 596
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
81
Perplexity
73
Gemini
84

About

Zoetis Inc. is the world's largest animal health company, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and other technologies for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Spun off from Pfizer in 2013, Zoetis has maintained its position as the global leader in animal health with approximately 300 product lines serving veterinarians, livestock producers, and pet owners in over 100 countries.

Full profile

AI Visibility Head-to-Head

78
Overall Score
79
#41
Category Rank
#31
75
AI Consensus
66
stable
Trend
stable
73
ChatGPT
81
74
Perplexity
73
82
Gemini
84
81
Claude
73
76
Grok
84

Key Details

Category
Enterprise
Animal Health
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Zoetis
Animal Health

Integrations

Only Edwards Lifesciences
Edwards Lifesciences is classified as company. Zoetis is classified as company (part of Pfizer).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.